CD4 Update

RNS Number : 9151O

Omega Diagnostics Group PLC

26 September 2013

 



Omega Diagnostics Group PLC

("Omega" or the "Company")

CD4 Update

Omega (AIM:ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update on its CD4 technology transfer project.

Further to the update given at the time of our final results in July, we selected a preferred manufacturing protocol to produce prototype devices to undertake a three-batch evaluation.  We have reviewed the results from patient samples tested using the first reference batch and there has been more variability in the results than expected.  This has generated some additional work as we refine production processes.  We continue to work closely with the Burnet Institute with the aim of achieving a successful transfer of the technology and we estimate that the additional work to complete the three-batch evaluation could now take until the end of December 2013.  We will reaffirm this timeline by the end of October 2013.

The Group intends to announce a trading update on 17 October 2013.

Contacts:

Omega Diagnostics Group PLC	Tel: [phone]
Andrew Shepherd, Chief Executive	www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
Jag Grewal, Group Sales and Marketing Director
finnCap Ltd	Tel: [phone]
Geoff Nash/Christopher Raggett (Corporate Finance)
Stephen Norcross/Mia Gardner (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

 

END

 

 

MSCLAMATMBJTBRJ